Meeting on the Mesa 2021 | Future advancements in tissue engineering

Petter Björquist, PhD, VERIGRAFT, Göteborg, Sweden, discusses some key remaining barriers in the tissue engineering. Commercialization of tissue engineered products remain a challenge, despite decellularization and reconditioning being processes that are widely known and used. Usage of stem cells additionally complicates matters from a regulatory perspective due to time, cost, and potential safety risks. Wider adoption of tissue-engineered products will require using materials such as blood which can reduce time and cost restraints. This interview took place at Meeting on the Mesa 2021.